We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

ALKS
Alkermes plc
NasdaqGS
People also watch : ALXN INCY BMRN NBIX AFFX
49.90 1.77 (3.68%)

After hours: 49.910.01 (0.02%) as of 4:48 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close 48.13
Open 49.00
Bid 45.00 x 100
Ask 65.10 x 100
52wk Range 27.14 - 80.71
Day's Range 48.28 - 50.06
Volume 1,174,550
Avg Vol (3m) 979,808
As of 4:00 PM EDT. Market closed.
  • Alkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook
    Zacks 2 days ago

    Alkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook

    Alkermes (ALKS) reported a narrower-than-expected, second-quarter 2016 loss while revenues beat estimates; the company revised its outlook for 2016.

  • Associated Press 3 days ago

    Alkermes reports 2Q loss

    On a per-share basis, the Dublin 4, Ireland-based company said it had a loss of 31 cents. Losses, adjusted for stock option expense and non-recurring costs, were 1 cent per share. The results surpassed ...

  • A Look At Recro Pharma Inc (REPH) and Alkermes Plc (ALKS)’s Topline Triumph
    Insider Monkey 4 days ago

    A Look At Recro Pharma Inc (REPH) and Alkermes Plc (ALKS)’s Topline Triumph

    Recro Pharma Inc (NASDAQ:REPH) is up more than 27% on Wednesday after announcing data from its lead acute pain trial. The company has developed an IV formulation of an already established drug, and is currently enrolling in the second of two pivotals that will form the basis of a New Drug Application if all runs smoothly. […]

  • TheStreet.com 4 days ago

    Jim Cramer's Top Takeaways: Acacia Communications, KeyCorp, Alkermes

    Cramer says to be careful with Acacia Communications but he's a big fan of KeyCorp.

  • Cramer Remix: It's time for Jack Dorsey to make a choice
    CNBC 4 days ago

    Cramer Remix: It's time for Jack Dorsey to make a choice

    Jim Cramer says Twitter CEO Jack Dorsey has a tough decision. You thought 'Sophie's Choice' was hard? This could be worse.

  • Barrons.com 5 days ago

    [$$] Three Biotech Q2 Reports Hold Potential

    Guggenheim Securities Acorda Therapeutics, Alkermes and Alexion Pharmaceuticals report second-quarter earnings on Thursday, July 28, before the market opens. We suspect Acorda (ticker: ACOR) (rated at ...

  • Alkermes Plc – Value Analysis (NASDAQ:ALKS) : June 21, 2016
    Capital Cube last month

    Alkermes Plc – Value Analysis (NASDAQ:ALKS) : June 21, 2016

    Click here to see latest analysisCapitalcube gives Alkermes Plc a score of 25.Our analysis is based on comparing Alkermes Plc with the following peers – Acorda Therapeutics, Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Novartis AG Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Sanofi Sponsored ADR, Zogenix, Inc., Pfizer Inc. and Astrazeneca PLC Sponsored […] (Read more...) The post Alkermes Plc – Value Analysis (NASDAQ:ALKS) : June 21, 2016 appeared first on CapitalCube.

  • Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : June 20, 2016
    Capital Cube last month

    Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : June 20, 2016

    Click here to see latest analysis*Disclaimer : This is as of previous day’s closing price.Technical IndicatorsBelow is a quick look at 5 technical indicators for Alkermes Plc. More studies are available on the Technical Chart.IndicatorSignalClosing Price above/below 50 Day Moving AverageBearishClosing Price above/below 200 Day Moving AverageBearish50 Day Moving Average above/below 200 Day Moving AverageBearishRSI […] (Read more...) The post Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : June 20, 2016 appeared first on CapitalCube.

  • Capital Cube 2 months ago

    ETF’s with exposure to Alkermes Plc : June 8, 2016

    Click here to see latest analysis*Disclaimer : This is as of previous day’s closeETF’s with exposure to Alkermes PlcHere are 5 ETF’s with the largest exposure to ALKS-US. Comparing the performance and risk of Alkermes Plc with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns […] (Read more...) The post ETF’s with exposure to Alkermes Plc : June 8, 2016 appeared first on CapitalCube.

  • Market Realist 2 months ago

    Alkermes Rises on Evercore’s ‘Buy’ Rating, Buying Support

    Alkermes (ALKS) was the top performer within the mid-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB), rising 4.1% on May 27, 2016.